OpportunityTitle: CBER FY20 FOA for AAV vector manufacturing for diseases affecting very small populations (R01) Clinical Trial Not Allowed
AdditionalInformationOnEligibility: Higher Education Institutions  &#8226; Public/State Controlled Institutions of Higher Education   &#8226; Private Institutions of Higher Education     The following types of Higher Education Institutions are always encouraged to apply for FDA support as Public or Private Institutions of Higher Education:   o Hispanic-serving Institutions  o Historically Black Colleges and Universities (HBCUs)  o Tribally Controlled Colleges and Universities (TCCUs)   o Alaska Native and Native Hawaiian Serving Institutions  o Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)    Nonprofits Other Than Institutions of Higher Education  &#8226; Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)   &#8226; Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)     For-Profit Organizations  &#8226; Small Businesses  &#8226; For-Profit Organizations (Other than Small Businesses)    Governments  &#8226; State Governments   &#8226; County Governments  &#8226; City or Township Governments  &#8226; Special District Governments  &#8226; Indian/Native American Tribal Governments (Federally Recognized)   &#8226; Indian/Native American Tribal Governments (Other than Federally Recognized)  &#8226; Eligible Agencies of the Federal Government  &#8226; U.S. Territory or Possession    Other  &#8226; Independent School Districts  &#8226; Public Housing Authorities/Indian Housing Authorities  &#8226; Native American Tribal Organizations (other than Federally recognized tribal governments)  &#8226; Faith-based or Community-based Organizations  &#8226; Regional Organizations  &#8226; Non-domestic (non-U.S.) Entities (Foreign Institutions)
Description: CBER seeks to advance the development of gene therapies for diseases affecting very small populations, potentially even single individuals, by enhancing innovations in the manufacture of Adeno-associated virus (AAV) vectors.
GrantorContactEmailDescription: work email
GrantorContactText: Gordana Zuber &lt;br/&gt;Grant Management Specialist &lt;br/&gt;Phone 301-348-1747